Inhibition of hyperactivated mTORC1, which results from loss of the TSC1/TSC2 tumor suppressor complex, is a specific molecular target for PEComas therapy. This evidence concerns the gene TSC1 and neoplasm with perivascular epithelioid cell differentiation.